Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR

Cell Death and Disease

Volumn 2, Issue 4, 2011, Pages

  Caraglia, M ^a   Giuberti, G ^a   Marra, M ^a   Addeo, R ^b   Montella, L ^b   Murolo, M ^a   Sperlongano, P ^a   Vincenzi, B ^c   Naviglio, S ^a   Del Prete, S ^b   Abbruzzese, A ^a   Stiuso, P ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Erk phosphorylation; Hepatocellular carcino M.A.; Octreotide LAR; Oxidative stress; Sorafenib; Superoxide dismutase

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; OCTREOTIDE; OXYGEN; REACTIVE OXYGEN METABOLITE; SORAFENIB; SUPEROXIDE DISMUTASE; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; TUMOR MARKER;

ARTICLE; BLOOD LEVEL; CANCER PATIENT; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; DELAYED RELEASE FORMULATION; DRUG RESISTANCE; LIVER TUMOR; METABOLISM; MONONUCLEAR CELL; PHOSPHORYLATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; OCTREOTIDE; OXIDATIVE STRESS; PHOSPHORYLATION; PYRIDINES; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79959966423     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.34     Document Type: Article

References (41)

1. Bosch FX, Ribes J, Díaz M, Clé ries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16. (Pubitemid 39423365)
2. Larson AM. The epidemiology of hepatocellular carcinoma in HCV. Curr Hepat Reps 2005; 4: 145-152.
3. Levi F, Lucchini F, Negri E, La Vecchia C. Continuing declines in cancer mortality in the European Union. Ann Oncol 2007; 18: 593-595. (Pubitemid 46359644)
4. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology; risk factors; and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963: 13-20. (Pubitemid 34721691)
5. La Vecchia C, Negri E, Pilucchi C. The rise and fall in primary liver cancer mortality in Italy. Dig Liver Dis 2002; 34: 169-171. (Pubitemid 34269559)
6. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni Jr JF. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290-296. (Pubitemid 32911426)
7. Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 2009; 49: 1962-1971.
8. Forner A, Hessheimer AJ, Real IM, Bruix J. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 2006; 60: 89-98. (Pubitemid 44740494)
9. Yau T, Chan P, Epstein R, Poon RTP. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009; 29: 10-17.
10. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442. (Pubitemid 36152543)
11. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346. (Pubitemid 35154440)
12. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-279. (Pubitemid 44301348)
13. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22. (Pubitemid 37328883)
14. Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS et al. Over-expression of c-raf-1 protooncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 2004; 29: 113-121. (Pubitemid 38667508)
15. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310. (Pubitemid 46763022)
16. Caraglia M, Tassone P, Marra M, Budillon A, Venuta S, Tagliaferri P. Targeting Raf-kinase: molecular rationales and translational issues. Ann Oncol 2006; 17(Suppl 7): 124-127.
17. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al. Sorafenib blocks the RAF/MEK/ERK pathway; inhibits tumor angiogenesis; and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858. (Pubitemid 46094197)
18. Blä ker M, Schmitz M, Gocht A, Burghardt S, Schulz M, Brö ring DC et al. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 2004; 41: 112-118. (Pubitemid 39005161)
19. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-254.
20. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007; 13: 3164-3170. (Pubitemid 47064577)
21. Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K et al. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. Clin Adv Hematol Oncol 2008; 6: 44-54. (Pubitemid 351484771)
22. Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci 2008; 53: 2359-2365.
23. Montella L, Addeo R, Caraglia M, Faiola V, Guarrasi R, Vincenzi B et al. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience. Oncol Rep 2008; 20: 385-390.
24. Del Prete S, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 2010; 66: 837-844.
25. Clemente C, Elba S, Buongiorno G, Guerra V, D'Attoma B, Orlando A et al. Manganese superoxide dismutase activity and incidence of hepatocellular carcinoma in patients with Child-Pugh class A liver cirrhosis: a 7-year follow-up study. Liver Int 2007; 27: 791-797. (Pubitemid 47062046)
26. Liaw KY, Lee PH, Wu FC, Tsai JS, Lin-Shiau SY. Zinc; copper; and superoxide dismutase in hepatocellular carcinoma. Am J Gastroenterol 1997; 92: 2260-2263.
27. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007; 117: 2713-2722. (Pubitemid 47494371)
28. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A et al. Activation of mitogenactivated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998; 27: 951-958. (Pubitemid 28160479)
29. Stowers SJ, Wiseman RW, Ward JM, Miller JA, Miller EC, Anderson MW et al. Detection of activated proto-oncogenes in N-nitrosodiethylamine-induced liver tumors: a comparison between B6C3F1 mice and Fisher 344 rats. Carcinogenesis 1988; 9: 271-276. (Pubitemid 18037991)
30. Calvisi DF, Pinna F, Meloni F, Ladu S, Pellegrino R, Sini M et al. Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma. Cancer Res 2008; 68: 4192-4200.
31. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
32. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300. (Pubitemid 46630787)
33. Kim WH, Goo SY, Lee KH, Park SJ. Vibrio vulnificus-induced cell death of human mononuclear cells requires ROS-dependent activation of p38 and ERK 1/2 MAPKs. Immunol Invest 2009; 38: 31-48.
34. Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, Shankey TV. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry 2005; 67: 4-17. (Pubitemid 41318288)
35. Wen-Sheng W. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2. Cancer Lett 2006; 28: 27-35. (Pubitemid 43946586)
36. Ridnour LA, Thomas DD, Switzer C, Flores-Santana W, Isenberg JS, Ambs S et al. Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide 2008; 19: 73-76.
37. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 2007; 120: 796-805. (Pubitemid 46175399)
38. Pervin S, Singh R, Freije WA, Chaudhuri G. MKP-1-induced dephosphorylation of extracellular signal-regulated kinase is essential for triggering nitric oxide-induced apoptosis in human breast cancer cell lines: implications in breast cancer. Cancer Res 2003; 63: 8853-8860. (Pubitemid 38064065)
39. Correale P, Campoccia G, Tsang KY, Micheli L, Cusi MG, Sabatino M et al. Recruitment of dendritic cells and enhanced antigen specific immune-reactivity in cancer patients treated with hrGM-CSF (Molgramostim) and hr IL-2: results from a phase Ib clinical trial. Eur J Cancer 2001; 37: 892-902. (Pubitemid 32323968)
40. Titheradge A. The enzymatic measurement of nitrate and nitrite. Methods Mol Biol 1998; 100: 83-91.
41. Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, Fiengo A et al. C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ 2007; 14: 952-962 (Pubitemid 46629834)